Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Osleriana

Osleriana ARAFATE 'sucralfate/Marion BRIEF SUMMARY CONTRAINDICATIONS There are no known contraindications to the use of sucralfate. PRECAUTIONS is Duodenal ulcer a chronic, recurrent disease. While short- with can result In heal¬ term treatment sucralfate complete of of with the ulcer, a successful course treatment sucralfate ing not to The second is a much more difficult surrounded as it is should be alter the frequency expected post-healing great problem one, or of duodenal ulcération. severity with connected with the and of a obstacles inextricably growth expansion Animal Interactions: studies have shown that Drug new For the United had been the States simultaneous CARAFATE comparatively country. years largest the administration of with tetracy- or will in a in the scientific market of the and in cline, cimetidine result borrower more the phenytoin, statistically sig¬ world, particularly in nificant reduction the of these This bioavailability agents. sciences to medicine. To the best that the world our relating get offered, be in interaction appears to nonsystemic origin, presumably had men to here and there a of was these CARAFATE in young go abroad; only laboratory from bound resulting agents being by tract. The of or and then as a rule for The the these http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Osleriana

JAMA , Volume 257 (21) – Jun 5, 1987

Osleriana

Abstract

ARAFATE 'sucralfate/Marion BRIEF SUMMARY CONTRAINDICATIONS There are no known contraindications to the use of sucralfate. PRECAUTIONS is Duodenal ulcer a chronic, recurrent disease. While short- with can result In heal¬ term treatment sucralfate complete of of with the ulcer, a successful course treatment sucralfate ing not to The second is a much more difficult surrounded as it is should be alter the frequency expected post-healing great problem one, or of duodenal...
Loading next page...
 
/lp/american-medical-association/osleriana-gy7bBZeI59

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1987 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1987.03390210044008
Publisher site
See Article on Publisher Site

Abstract

ARAFATE 'sucralfate/Marion BRIEF SUMMARY CONTRAINDICATIONS There are no known contraindications to the use of sucralfate. PRECAUTIONS is Duodenal ulcer a chronic, recurrent disease. While short- with can result In heal¬ term treatment sucralfate complete of of with the ulcer, a successful course treatment sucralfate ing not to The second is a much more difficult surrounded as it is should be alter the frequency expected post-healing great problem one, or of duodenal ulcération. severity with connected with the and of a obstacles inextricably growth expansion Animal Interactions: studies have shown that Drug new For the United had been the States simultaneous CARAFATE comparatively country. years largest the administration of with tetracy- or will in a in the scientific market of the and in cline, cimetidine result borrower more the phenytoin, statistically sig¬ world, particularly in nificant reduction the of these This bioavailability agents. sciences to medicine. To the best that the world our relating get offered, be in interaction appears to nonsystemic origin, presumably had men to here and there a of was these CARAFATE in young go abroad; only laboratory from bound resulting agents being by tract. The of or and then as a rule for The the these

Journal

JAMAAmerican Medical Association

Published: Jun 5, 1987

There are no references for this article.